For many biopharmas, it takes years of hard work to transition from being a clinical-stage drugmaker to a commercial one.

While Johnson & Johnson hopes to soon resolve more than 60,000 talc lawsuits with an $8 billion bankruptcy settlement in the ...

For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...

Every year, Fierce’s pharma, biotech, and medtech teams come together to spotlight some of the fiercest women in life s | ...

New York-based health comms agency Calcium+Company is living up to its name, strengthening the bones of its business with the ...

Few pharmaceutical products have taken the market by storm like Roche’s Vabysmo. | Interim results from a late-stage trial of ...

As the biopharma industry braces for a second term under President-elect Donald Trump, speculation is swirling around the ...

While president-elect Donald Trump has already made his leadership picks for the Department of Health and Human Services (HHS ...

Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are ...

The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...

As he introduced Novartis’ meet-the-management event Thursday in London, CEO Vas Narasimhan hammered home Novartis’ status as ...

Australia’s CSL is winding down operations at a cell and gene therapy R&D site in California. Kyowa Kirin inked a commercialization and development deal with Kuro Oncology. Plus more.